New Frontiers in 3D Cell Technologies
Fostering discussion of transformative 3D in vitro cell technologies from advanced disease modeling to organ-on-a-chip solutions
Virtual KOL Roundtables ● In-person and Digital Symposia ● Curated 3D In Vitro News Digests
Are you ready for the future of preclinical drug testing?
Organ on a chip systems | scalable 3D disease modeling platforms | animal testing alternatives | highly predictive drug safety screening
Join the conversion. Help shape the future.
New Frontiers in 3D Technologies is going digital! This year we’re introducing a virtual roundtable series featuring key opinion leaders who are on a mission to transform drug discovery and safety testing. We’re also planning a virtual symposium that will bring together pharma and biotech thought-leaders, research scientists, and regulatory experts to discuss innovative new 3D cell technologies for drug efficacy and safety testing. To help you stay informed about movers and shakers in 3D, we’ve launched a curated news digest focused on 3D in vitro breakthroughs. Our aim is to make it easy and convenient for us all to stay in touch and stay informed during this pandemic and beyond.
- Learn about practical applications for the latest generation of 3D in vitro models that have successfully transitioned from R&D evaluations to indispensable for everyday use in industry
- Discuss 3D technology trends and real-world implementation challenges
- Discover disease modeling platforms, assay strategies, and readout techniques that could transform how your organization does drug discovery and development
- Debate how best to apply emerging tools for organ-on-a-chip systems.
- Network with influencers in the fields of metabolic disease, oncology, and toxicology
- Share how you are applying 3D cell-based technology in your work by submitting an abstract for a poster or oral presentation.
Human Disease Modeling
Alternatives to Animal testing
Drug Safety Screening
Featured Roundtable Event
Now available as a podcast.
Type 1 Diabetes: Emerging Perspectives on Disease Pathogenesis, Prevention and Treatment
An engaging discussion on major discoveries and knowledge gaps in our understanding of T1D pathogenesis and emerging therapies to treat or prevent T1D, and their potential challenges.
Burcak Yesildag is the Vice President of the Diabetes Research at InSphero AG. She received her MSc degree in Biochemistry and PhD degree in Translation Biomedicine from ETHZ (Swiss Federal Institute of Technology Zurich).
Matthias Hebrok is Hurlbut-Johnson Distinguished Professor in Diabetes Research at the Diabetes Center at the University of California San Francisco. He received his Diploma degree in Cell Biology from the Albert-Ludwigs University, performed his PhD thesis at the Max-Planck-Institute, and conducted his postdoctoral research at HHMI at Harvard University.
Matthias von Herrath holds a dual appointment as Vice President and Senior Medical Officer at Novo Nordisk and Professor at the La Jolla Institute for Immunology Center for Autoimmunity and Inflammation. He received his medical degree from the Freiburg Medical School in Germany and completed his residency work in the Internal Medicine/Immunology department at the Freiburg Medical Center.
Mark Peakman is a Senior Director of Autoimmunity and Type 1 Diabetes research at Sanofi. He trained in medicine at University College London and pursued postgraduate training in clinical immunology. After his PhD on the immune system in type 1 diabetes he held a senior clinical research fellowship at the University of Pittsburgh.
Call for Abstracts
New Frontiers in 3D invites scientists, bioengineers, academic researchers, and innovation leaders to submit abstracts featuring innovative applications of 3D Cell Technology for consideration for poster and oral presentations at our 2021 meeting. Check back for details and abstract submission guidelines.
New Frontiers in 3D plans to invite a select group of innovative 3D cell-based solution providers to sponsor our 2021 virtual meeting and showcase products that we believe will be of interest to scientists, researchers, regulatory agencies, and others in the field. If you haven’t already received an invitation to participate, contact us for more information.